UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000060552 |
|---|---|
| Receipt number | R000069161 |
| Scientific Title | Physicians' practical status about treat to target in ulcerative colitis |
| Date of disclosure of the study information | 2026/02/02 |
| Last modified on | 2026/02/02 15:28:16 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Physicians' practical status about treat to target in ulcerative colitis
Acronym
PICTURE survey
Scientific Title
Physicians' practical status about treat to target in ulcerative colitis
Scientific Title:Acronym
PICTURE survey
Region
| Japan |
Condition
Condition
Ulcerative colitis
Classification by specialty
| Medicine in general | Gastroenterology | Gastrointestinal surgery |
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The objective of this study is to elucidate, through an internet based survey, the level of awareness and implementation of the treat to target (T2T) strategy in the clinical management of ulcerative colitis (UC) in Japan, and to characterize the current patterns of biomarker utilization as well as the factors underlying clinical decision making.
Basic objectives2
Others
Basic objectives -Others
Treat to Target (T2T) is a strategic treatment management concept in which disease activity is assessed using objective measures, and therapeutic decisions are adjusted toward pre defined treatment targets. In ulcerative colitis (UC), not only clinical remission but also mucosal healing and normalization of inflammatory biomarkers are regarded as important multidimensional treatment goals, and the implementation of such an approach has been internationally recommended in STRIDE II.
The objective of this study is to elucidate, through an internet based survey, the level of awareness and implementation of the treat to target (T2T) strategy in the clinical management of ulcerative colitis (UC) in Japan, as well as to characterize the current patterns of biomarker utilization and the factors influencing clinical decision making.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Awareness, implementation, and related aspects of the T2T strategy
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Physicians who provide care for patients with ulcerative colitis and are registered in the research cooperation panel of Cross Marketing Co., Ltd., and who have agreed to participate in this survey
Key exclusion criteria
None
Target sample size
300
Research contact person
Name of lead principal investigator
| 1st name | Yoshiyuki |
| Middle name | |
| Last name | Hosoi |
Organization
EA Pharma Co., Ltd.
Division name
Medical Science Group, Medical Dept.
Zip code
104-0042
Address
Sumitomo Irifune Bldg, 2-1-1, Irifune, Chuo-ku, Tokyo 104-0042, Japan
TEL
080-1060-3262
yoshiyuki_hosoi@eapharma.co.jp
Public contact
Name of contact person
| 1st name | Yoshiyuki |
| Middle name | |
| Last name | Hosoi |
Organization
EA Pharma Co., Ltd.
Division name
Medical Science Group, Medical Dept.
Zip code
104-0042
Address
Sumitomo Irifune Bldg, 2-1-1, Irifune, Chuo-ku, Tokyo 104-0042, Japan
TEL
080-1060-3262
Homepage URL
yoshiyuki_hosoi@eapharma.co.jp
Sponsor or person
Institute
EA Pharma Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
EA Pharma Co., Ltd.
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Yamauchi Clinic Research Ethics Committee
Address
1-15-9 Jiyugaoka, Meguro-ku, Tokyo
Tel
03-6777-1490
c-irb_ug@neues.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 02 | Month | 02 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2026 | Year | 01 | Month | 15 | Day |
Date of IRB
Anticipated trial start date
| 2026 | Year | 02 | Month | 12 | Day |
Last follow-up date
| 2026 | Year | 02 | Month | 27 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
None
Management information
Registered date
| 2026 | Year | 02 | Month | 02 | Day |
Last modified on
| 2026 | Year | 02 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000069161
